0.4600
+0.0498
+(12.14%)
At close: January 24 at 4:00:00 PM EST
0.4720
+0.01
+(2.61%)
After hours: January 24 at 6:24:25 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, CEO & Director | 820.88k | -- | 1972 |
| Dr. Michael F. Burgess M.D., MBChB, Ph.D. | Executive Director | -- | -- | 1963 |
| Ms. Wendy Worcester CFA, CPA | VP, Principal Finance & Accounting Officer | -- | -- | -- |
| Ms. Saryah Azmat | Chief Operating Officer | 479.73k | -- | 1989 |
| Dr. David Stojdl Ph.D. | Senior Vice President of Research & Discovery | -- | -- | -- |
| Dr. Ines Verdon M.D. | Senior Vice President of Clinical Development | -- | -- | -- |
| Dr. Michael Fitch Ph.D. | Senior Vice President of Manufacturing | -- | -- | -- |
Turnstone Biologics Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 80
Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Corporate Governance
Turnstone Biologics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Related Tickers
SPRB Spruce Biosciences, Inc.
0.3819
-0.37%
NXTC NextCure, Inc.
0.8230
-4.08%
SNSE Sensei Biotherapeutics, Inc.
0.5336
+0.68%
KRON Kronos Bio, Inc.
1.0400
-2.80%
BOLD Boundless Bio, Inc.
2.4100
-5.12%
HLVX HilleVax, Inc.
1.9700
+1.03%
ELDN Eledon Pharmaceuticals, Inc.
4.4300
+4.24%
RLYB Rallybio Corporation
0.8800
-3.87%
LVTX LAVA Therapeutics N.V.
0.9500
-1.35%
NBY NovaBay Pharmaceuticals, Inc.
0.7176
+1.06%